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Aspergillus species are the major life threatening fungal pathogens in transplant patients. Germination of inhaled fungal spores initiates
infection, causes severe pneumonia, and has a mortality of N50%. This is leading to the consideration of pre-exposure prophylaxis to prevent
infection. We made a very low MWt amphotericin B-polymethacrylic acid nanoparticle. It was not toxic to lung epithelial cells or monocyte-
derived-macrophages in-vitro, or in an in-vivo transplant immuno-suppression mouse model of life threatening invasive aspergillosis. Three
days of nebuliser based prophylaxis delivered the nanoparticle effectively to lung and prevented both fungal growth and lung inflammation.
Protection from disease was associated with N99% killing of the Aspergillus and a 90% reduction in lung TNF-α; the primary driver of tissue
destructive immuno-pathology. This study provides in-vivo proof-of-principle that very small and cost-effective nanoparticles can be made
simply, and delivered safely and effectively to lung by the aerosol route to prevent fungal infections.
From the Clinical Editor: Aspergillus is an opportunistic pathogen, which affects immunocompromised patients. One novel way to help
fight against this infection is pre-exposure prophylaxis. The authors here made PMA based anionic hydrogels carrying amphotericin B, with
mucoadhesive behavior. They showed that aerosol route of the drug was very effective in protecting against the disease in an in-vivo model
and should provide a stepping-stone towards clinical trials in the future.
© 2015 TheAuthors. Published by Elsevier Inc. This is an open access article under the CCBY license (http://creativecommons.org/licenses/by/4.0/).
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chemistry are a rapidly growing area of interest in nanomedicine.1–3
Self-assembled hydrogels are also being developed to encapsulate
hydrophobic drugs for sustained drug delivery.4 These materials are
being investigated and applied clinically for direct delivery of drugs
to sites of disease.5
We have previously shown that established, scalable and
low-cost synthetic chemistries can be used to make a water soluble
amphotericin B-PMA (AmB-PMA) using an 18.5 kDa poly-
methacrylic acid-Na. It was safe and subcutaneous injection led to
rapid cure of cutaneous leishmaniasis in a non-healing disease
mouse model.6 PMA based anionic hydrogels also exhibit
mucoadhesive behaviour that enables continuous release of active
drug for N8 h in the respiratory tract.7 This has led us to define theFunding: MRC Clinician Scientist Fellowship award [G0902260/1] &
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for aerosol delivery to the lung.Our aimwas to provide a simple, low
toxicity, and highly effective means of pre-exposure prophylaxis
against invasive aspergillosis in immuno-suppressed patients; e.g.
solid organ transplants, hematopoietic stem cell transplants, AIDS,
cancer. This is because patient mortality from invasive aspergillosis
remains N50% despite improvements in immuno-suppressive drug
regimens and new antifungal drugs.8,9 Prevention rather than cure is
now becoming the preferred clinical option.
Respiratory inhalation of environment spores is responsible for
90% of all cases of invasive aspergillosis.10–12 Germination of
spores in small bronchioles initiates infection, causes severe
pneumonia, and has a mortality of N50%.13 This led us to consider
pre-exposure prophylaxis to prevent infection with as few inhaled
doses as possible, and without pulmonary toxicity.Methods
Synthesis and characterisation
These fully hydrolysed analytical standard grade poly-
methacrylic acid sodium salts were used: 18,500 Da PMA; Mprticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Mp 7830, Mw 7750 (Sigma-Aldrich 02355) and 3520 Da PMA;
Mp 3480, Mw 3520 (Polymer Standards Services Mainz [PSSM]
PSS-pma 3.5k) and 1700 Da PMA; Mp 1670, Mw 1700 (PSSM
PSS-pma1.6k) and 1270 Da PMA; Mp 1250, Mw 1270
(Sigma-Aldrich 02351).
The following aspects of the synthesis previously described6
were further simplified and optimised. 50 mg PMA-Na was
dissolved in 10 ml water and solubilised on a rotary shaker at
20°C overnight. 9.7 ml DMSO was added to 50 mg AmB,
sealed under argon, and stirred for 3 h. 10 ml of 5 mg/ml
PMA-Na solution was treated twice with activated charcoal
(12.5 mg, 25% w/w) to remove endotoxin. After each treatment,
the charcoal-PMA slurry was centrifuged at 13,000 ×g for
8 min. The supernatant was removed and filtered twice through a
0.2 μm filter to remove non-solubilised particles. The AmB
solution (2 ml) was added to a round-bottom glass flask and 1 N
NaOH (100 μl, 15 μl/3 s) added dropwise, followed by the
addition of the PMA-Na solution (2 ml) and 8 ml water, and
stirred for 1 h at 20 °C. It was then transferred to a Float-a-Lyzer
(500-1000 Da cut-off) or Slide-a-Lyzer cassette (2-3.5 kDa
cut-off depending upon PMA-Na size) and dialysed against
sterile water for 4 h at 4 °C. Water was changed and the dialysis
continued for 20 h at 4 °C; during this time it was important to
regularly adjust the pH of the AmB-PMA dialysate to 12. The
dialysed solution was lyophilised to give a pale yellow powder.
The amount of AmB in AmB-PMA was determined by UV
spectroscopy as described.6
In-vitro biology
Anti-fungal activity against A. fumigatus was determined
using the Clinical & Laboratory Standards Institute (CLSI)
method.14 A. fumigatus strain CEA10 conidia were harvested
from an SDA plate in 0.1% Tween 20 and filtered through
Miracloth (Millipore). Conidia were re-suspended in sterile
saline, counted, and adjusted to 104-105 conidia/ml. Doubling
dilutions of the AmB-PMA nanoparticles in 100 μl of RPMI
1640, 2% glucose, 0.165 mol/l MOPS pH 7.0 (range
0.0156-16 μg/ml) were dispensed into 96-well plates and
inoculated with 100 μl of conidia (104-105 conidia/ml) per
well in accordance with the CLSI M38a protocol. Plates were
incubated in a sealed container for 48 h at 37 °C and then
assayed for fungal growth by microscopy. The minimum
inhibitory concentration (MIC) was defined as the concentration
beyond which no fungal growth occurred.
Fungal burden in mouse lung
The first method used was colony forming unit (CFU)
counting. Lung tissue was mechanically disrupted in 1 ml sterile
saline and the fungal spores and hyphae released serially diluted
and spread on SDA plates. They were then incubated for 24 h at
37 °C and the number of A. fumigatus colonies counted. The
second method used quantitative PCR. Tissue was homogenised
in 250 μl PBS and DNA extracted using a DNeasy Blood and
Tissue kit (Qiagen). 180 μl of buffer ATL and 20 μl proteinase
K solution were added to 250 μl homogenate lung and incubated
overnight at 56 °C. These samples were then processedaccording to the manufacturer’s instructions and applied to
DNeasy columns, and the DNA diluted in 200 μl elution buffer.
The ADR1 (CAGGCTGGCCGCATTG) and ASF1
(GCACGTGAAATTGTTGAAAGG) primer pairs were used
to amplify the fungal 28S rRNA gene with amplified product
detection based upon hybridisation to the ASP28P TaqMan
fluorescent probe [6 FAM] CATTCGTGCCGGTG
TACTTCCCCG [TAM]. The fungal burden was quantitated
by PCR and normalised against murine β-actin using the forward
primer CGAGCACAGCTTCTTTGCAG and the reverse primer
CCCATGGTGTCCGTTCTGA as described.15
Mouse lung cytokine assays
Quantitative RT-PCR of mRNA in mouse lung was used
for the analysis of TNF-α, IFN-γ, MIP-1β, IL-10 and iNOS
as described.6,9,16
In-vivo efficacy
BALB/c and C57BL/6 mouse models of life threatening
invasive aspergillosis in solid organ transplantation were used as
described.17,18 In brief, mice were immuno-suppressed with
125 mg/kg hydrocortisone given subcutaneously at day −3 and
day −1 before infection (which was defined as day 0), and again
at day +2 and +5 after infection. In addition, FK-506 was given
intraperitoneally at 1 mg/kg once daily from day −3 onwards.
On the day of infection, mice were given isoflourane
anaesthesia and 5 × 106 A. fumigatus CEA10 spores in 40 μl
normal saline inoculated intra-nasally; control mice received
normal saline only. They were culled on days +1, +2, +4 and
+8; control mice were culled on day +2 because they had lost
20% body weight. This new mouse model of invasive
aspergillosis in organ transplant patients is the first pathologi-
cally accurate representation of modern immuno-suppressive
drug regimens which use a combination of a steroid (hydrocor-
tisone) with a calcineurin inhibitor (FK-506; tacrolimus).17,18
A Perspex chamber that housed 4 mice was constructed using
themethod ofManunta et al.19 The clinically approvedAeroEclipse
II nebuliser, a disposable cost-effective and high output efficiency
nebuliser, was used for nebulising the AmB-PMA nanoparticle
after reconstitution in sterile water to give a yellow solution.
The nebuliser was operated by an air cylinder at 3 bar pressure with
8 l/min airflow as is conventional for nebulisation protocols in
patients. The total aerosolised dose of AmB in AmB-PMA
dispensed into the chamber ranged from 40 to 400 μg/nebulisation.
It was given on days −3, −2 and −1 before infection with A.
fumigatus (day 0) and was based upon previous industry animal
model protocols.20 Control mice received nebulised water only or
nebulised PMA-Na dissolved in water. After infection with A.
fumigatus, hydrocortisone and FK-506 were continued until the
mice were culled. No AmB-PMA was given after infection.
Ex-vivo efficacy of nanoparticle
This was determined by nebulising different doses of the
AmB-PMA with a Sabouraud dextrose agar plate placed inside
the perspex chamber. A. fumigatus (1 × 107) was then added to
the plate and incubated for 24 h at 37 °C.
Figure 1. In-vitro studies of AmB-PMA (3.52 kDa) [AP]: (A, B) Viability of A549 cells (A) and MDMs (B) with AmB-PMA (3.52 kDa) [AP] &
dexoycholate-AmB. 106 cells were incubated with AmB-PMA (□) or dexoycholate-AmB (○) for 3 h and cell viability determined by MTT. No toxicity of AP
was seen in epithelial A549 cells (n = 5) or monocyte-derived-macrophages (n = 25).(C) pH related solubility of AP in water. More free bioactive AmB was
released from the AmB-PMA (3.52 kDa) (□) at pH 5 (i.e. 28%) than from the AmB-PMA (18.5 kDa) (■) (i.e. 20%) (P b 0.01; n = 3). (D) The IFN-γ and
TNF-α immuno-stimulatory activity of AP on monocyte-derived-macrophages was not altered by the presence of therapeutically relevant doses of
hydrocortisone and FK-506. For IFN-γ: Normal = 10,080 ± 410 copies/105 copies HPRT; HC + FK-506 = 7280 ± 270 copies/105 copies HPRT; AP =
19,280 ± 840 copies/105 copies HPRT. For TNF-α: Normal = 203,600 ± 3500 copies/105 copies HPRT; HC + FK-506 = 79,300 ± 940 copies/105 copies
HPRT; AP = 6.29 × 106 ± 338,000 copies/105 copies HPRT.
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Formalin fixed sections of lung tissue were cut and stained with
PAS. ImageJ is a public domain Java image processing program
(http://rsbweb.nih.gov/ij/) that can be used to calculate the area and
pixel value statistics of user-defined selections. It was used to
quantitate lung inflammation in tissue sections17,18 (n = 3).
Data analysis
Graphpad Prism software was used. Results are shown as the
mean ± SEM.P valueswere determined using aMann–Whitney test.Results
PMA-Na polymers
No haemolysis occurred with any of the analytical standard
grade PMA-Na polymers used when they were incubated with
fresh human red blood cells for 1 h up to 2.5 mg/ml. In an MTT
assay, these PMA-Na polymers were not toxic to primary human
monocyte-derived-macrophages or to lung epithelium A549 cells
up to 500 μg/ml, and they had no immuno-modulatory activity
(Supplementary Figure 1). In addition, they had no antifungal
activity when tested against 11 isolates of A. fumigatus up to256 μg/ml. These results showed that there were no biological
characteristics that could distinguish between the various PMA-Na
polymers used.AmB-PMA characterisation with varying weight PMA-Na
No differences were seen by UV spectrophotometry between
the various AmB-PMAs synthesised and stored as pale yellow
powders using PMA-Na with a MWt range of 1.27-18.5 kDa. The
sustained alkalinisation of the AmB-PMA nanoparticle at pH 12
during dialysis was the crucial determinant of the peak UV
fluorescence shifting from329 nm, as seen for deoxycholate-AmB
(Fungizone, Squibb), to 324 nm as seen for liposomal AmB
(Ambisome, Gilead) (Supplementary Figure 2).6,21 All nanopar-
ticles were confirmed to be endotoxin free using a limulus
amoebocyte assay (i.e. endotoxin b0.06 EU/ml; EU standard for
water for injection) prior to biological testing.
When the antifungal activity of the AmB-PMA nanoparticles
was determined by MIC testing using 11 isolates of A. fumigatus
with deoxycholate-AmB as the positive control, their mean MICs
ranged from 0.75 μg/ml for AmB-PMA (18.5 kDa) to 0.125 μg/ml
for AmB-PMA (3.52 kDa) (n = 3). This compared to 0.25 μg/ml
for deoxycholate-AmB (Supplementary Table 1). These results
showed that theAmB-PMA (3.52 kDa) {AP},whoseAmB loading
Figure 2. Comparison of BALB/c and C57BL/6 mouse lung: (A) Percentage
inflammation in lung was similar in BALB/c and C57BL/6 mice (n = 3). (B)
IFN-γ in normal (i.e. immuno-competent) C57BL/6mouse lungwasmuch higher
than in normal BALB/cmouse lung. IFN-γwas depressed in immuno-suppressed
(IS) BALB/c and C57BL/6mouse lung on day +2 after infection (n = 4). Normal
IFN-γ for BALB/c mouse = 310 ± 56 copies/105 copies HPRT; Normal IFN-γ
for C57BL/6 mouse = 8230 ± 395 copies/105 copies HPRT.(C) There was a
large increase in TNF-α in immuno-suppressed (IS) BALB/c mouse lung at day
+2 after infection (P b 0.0001) (n = 4). Normal TNF-α for BALB/c mouse =
1230 ± 120 copies/105 copies HPRT; IS + AF (d + 2) TNF-α for BALB/c
mouse = 191,300 ± 51,700 copies/105 copies HPRT. Normal TNF-α for
C57BL/6 mouse = 191,300 ± 51,700 copies/105 copies HPRT; IS + AF
(d + 2) TNF-α for C57/BL mouse = 22,700 ± 3600 copies/105 copies HPRT.
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AmB (Fungizone, Squibb) and an AmB loading of 12.5% in
liposomal AmB (Ambisome, Gilead)), was the least toxic
nanoparticle to monocyte-derived-macrophages and also had the
greatest antifungal activity against A. fumigatus. This made AP the
best candidate for further in-vitro and in-vivo testing.
Detailed in-vitro characterisation of AP
AP was not toxic to either lung epithelium A549 cells
(Figure 1, A) or monocyte-derived-macrophages (Figure 1, B).
Changing the PMA-Na from MWt 18.5 kDa to 3.52 kDa changed
the diameter of the AmB-PMA nanoparticle from 94 ± 1 nm to
78 ± 9 nm respectively as measured by Dynamic Light Scattering.
This compares to a diameter of 75 nm for deoxycholate-AmB and
78 nm for liposomal-AmB.Nanoparticles of this size are effectively
delivered to the lung’s terminal bronchioles.22,23
At an alkaline pH, the carboxylic acid groups of PMA are
ionised and repel each other; this allows the PMAhydrogel to swell
and trap small molecules like AmB within its matrix. At an acidic
pH, the carboxylic acid groups are de-ionised and the hydrogel
collapses; this results in theAmBbeing released into solution.6We
found that more AmB was released from AP (i.e. 3.52 kDa) into
solution at pH 5 than from AmB-PMA (18.5 kDa); 28% versus
20% respectively (P b 0.01) (Figure 1, C).
The in-vitro immuno-modulatory activity of AP on monocyte-
derived-macrophages was also evaluated in the presence of
therapeutically relevant doses of hydrocortisone and FK-506 by
measuring the cytokines TNF-α& IFN-γ. Therewas no significant
effect of hydrocortisone or FK-506, or of the combination of
hydrocortisone and FK-506, on IFN-γ or TNF-α. In contrast, the
addition of AP significantly increased both IFN-γ (Figure 1, D)
and TNF-α (Figure 1, E).
A. fumigatus infection in BALB/c and C57BL/6 mouse species
There was minimal inflammation when normal BALB/c and
C57BL/6 mice were intra-nasally challenged with A. fumigatus
(0-6.5 ± 1.2% (n = 10)). When immuno-suppressed mice were
infected, there was a large increase in lung inflammation at day
+2 which was similar in BALB/c and C57BL/6 mice (60-74 ±
3% (n = 10)) (Figure 2, A). Although IFN-γ was similar in both
species after infection (Figure 2, B), TNF-α was much higher in
BALB/c mice (Figure 2, C). As a high level of TNF-α is known
to be the primary driver of the destructive immuno-pathology
associated with invasive aspergillosis in the lungs of immuno-
suppressed patients,9,17,18 this suggested that the BALB/c mouse
model of invasive aspergillosis was the most appropriate for
undertaking further evaluation of the in-vivo bioactivity of
pre-exposure prophylaxis with AP.
In-vitro efficacy of the AeroEclipse II in nebulising AP
The AeroEclipse II nebuliser was used to nebulise the
nanoparticle in the dose range 40-400 μg AmB in AP. Over a
30 min period, the aerosol spread evenly throughout the perspex
box and onto the agar plate in its bottom. The plate was then
inoculated with A. fumigatus and cultured for 24 h. Many
apergillus colonies grew at 40 μg of AmB in AP, and some
Figure 3. PAS stain histology of lung tissue: (A) Normal BALB/c mouse lung (×10). (B) Normal BALB/c mouse lung at day +2 after being exposed to A.
fumigatus (×10). The % inflammation in the tissue sections was 6.5 ± 2.1% (n = 4). (C) Immuno-suppressed and A. fumigatus infected BALB/c mouse lung at
day +2 (×10). The % inflammation in the tissue sections was 74 ± 3% (n = 6). (D) Immuno-suppressed BALB/c mouse lung with AP pre-exposure prophylaxis
of 300 μg AmB in AP for 3 days and A. fumigatus infection at day +2 (×10). The % inflammation in the tissue sections was 14 ± 3% (n = 6). (E, F)
Immuno-suppressed BALB/c mouse lung with AP prophylaxis and A. fumigatus infection at day +2 showing spores in terminal bronchioles (E; ×10) and in
alveolar macrophages (F; ×40). No invasive fungal hyphae were seen. A. fumigatus were occasionally seen as spores engulfed by alveolar macrophages; these
have been highlighted within the black circles.
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no fungal growth occurred with 300 μg of AmB in AP.AP pre-exposure prophylaxis in BALB/c mice at day +2
The immuno-suppressed and infected mice were culled at day
+2 after infection because of loss of 20% body weight. At a dose
of 40 μg AmB in AP, there was no prophylactic benefit seen
using any of the following parameters; histology, CFU,
quantitative PCR for Aspergillus ribosomal 28S rRNA, and
quantitative RT-PCR of mRNA for analysis of TNF-α, IFN-γ,
MIP-1β, IL-10 and iNOS in mouse lung (n = 6/group).
With a dose of 200 or 250 μg AmB inAP, themice did not lose
weight (i.e. b5%), and therewas a large reduction in fungal growth
when compared to the immuno-suppressed and infected controls.
However, fungal growth from the lungs at day +2 was not
eliminated by this dose; this only occurred when a dose of 300 μg
AmB in AP was used (Figure 3). No further benefit was seen by
increasing the dose to 400 μg AmB in AP. Therefore, the
additional studieswere performedwith a once daily dose of 300 μg
AmB in AP given for 3 consecutive days before infection.
At autopsy, the most striking difference was that lungs from
both normal and immuno-suppressed/infected/AP pre-exposure
prophylaxis mice had a normal macroscopic appearance when
compared to the blackened lungs of the immuno-suppressed/
infected mice. The percentage inflammation in BALB/c lung
with a dose of 300 μg AmB in AP (14 ± 2.3% (n = 6/group))
was similar to that seen in normal BALB/c mice exposed to
aspergillus spores (6.5 ± 2.1%; P = 0.1 (n = 4/group)). This wasconsiderably less than the inflammation seen in immuno-
suppressed/infected mice (74 ± 3%; P = 0.002 (n = 6)) (Figure 4).
The lung fungal burden at day +2 after infection showed a
large reduction in the pre-exposure prophylaxis AP group as
measured by both CFU and 28S rRNA analysis (P b 0.0001)
(n = 4) (Figure 5). Although there was no associated change in
IFN-γ (Figure 6, A), there was, in contrast, a large and sustained
reduction of 90% in TNF-α in the pre-exposure prophylaxis AP
group (P b 0.0001) (n = 4) (Figure 6, B) that was also reflected
in an 80% reduction in lung iNOS (P b 0.0001) (n = 4)
(Figure 6, C). This suggested that lung alveolar macrophage
activation did not occur when immuno-suppressed mice were
given pre-exposure prophylaxis with AP.
AP pre-exposure prophylaxis in BALB/c mice at day +8
The immuno-suppressed and infected mice were culled by day
+2 because of 20% weight loss. Their fungal burden at that time
was 320,000 ± 64,000 CFU/mouse; this figure was defined as
100%. In contrast, the fungal burden in the immuno-suppressed
mice at day +2, which had received pre-exposure prophylaxis with
AP was 0.88 ± 0.59%; i.e. a N99% reduction of the inoculum of
5 × 106 A. fumigatus CEA10 spores administered had been
eliminated in the first 48 h after infection by AP pre-exposure
prophylaxis. Furthermore, by day +8, these mice had lost only
10% of their body weight (n = 4), and the fungal burden in their
lungs was 14.1 ± 1.8% of that in mice that had not received AP
(Figure 7). There was no change in IFN-γ during the course of
this experiment (Figure 8, A). In contrast, TNF-α was only 10 ±
1.43% of that in immuno-suppressed/infected mice at day +2
Figure 4. Percentage inflammation in the tissue sections from BALB/c mouse
lung after prophylactic AP. There was a significant reduction in lung
inflammation (P = 0.002) after pre-exposure prophylaxis with AP at a dose
of 300 μg AmB given for 3 consecutive days. The degree of inflammation
seen (14 ± 3%) was similar to that seen in normal mice exposed to A.
fumigatus (P = 0.1; n = 4).
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(P b 0.0001) (n = 4) by day 8 (Figure 8, B).Figure 5. Fungal burden in immuno-suppressed BALB/c mouse lung after
pre-exposure prophylaxis with AP at day +2 post infection: (A) CFUs after
plating on agar (n = 4). At 0 μg AmB, the CFUs were 410,000 ± 88,600; at
200 μg AmB, the CFUs were 22,000 ± 6600, and at 300 μg AmB, the CFUs
were 3000 ± 1920 (a reduction of 99.3%). (B) As quantified by quantitative
PCR for the 28S rRNA gene (n = 4). At 0 μg AmB, the 28S rRNA copies/2500
murine β-actin copies were 15,070 ± 2900; at 200 μg AmB, they were 646 ±
99, and at 300 μg AmB, they were 349 ± 34 (a reduction of 86%).Discussion
Using a very small analytical standard grade polymethacrylic
acid24–26 and simple, optimised, established, scalable and low
cost synthetic chemistries, we have succeeded in turning
insoluble and toxic AmB into a 3.52 kDa water soluble
AmB-PMA nanoparticle of diameter 78 ± 9 nm. Its UV spectral
analysis was made identical to liposomal AmB by ensuring that
dialysis was performed at pH 12 (Supplementary Figure 2).6,21
The nanoparticle was soluble in water at 4 mg/ml and both stable
and bioactive after storage at 4 °C for 18 months.
In a new solid organ transplantation mouse model of invasive
aspergillosis that is representative of clinical practice today,17,18
three prophylactic doses of nebulised AP were sufficient to
protect BALB/c and C57BL/6 mice from the life threatening
pneumonia of invasive aspergillosis. The previous model of
Schmitt et al27 was developed in 1988 and used hydrocortisone
only as the immuno-suppressant. Our results suggest that 3 days
of pre-exposure prophylaxis could be sufficient to protect
immuno-suppressed patients from a range of life threatening
and invasive fungal infections of the lung given the broad
spectrum anti-fungal activity of AmB. The pre-exposure
prophylaxis approach described for preventing fungal infections
has both considerable clinical utility and cost saving potential.
By comparison, current approaches to invasive aspergillosis are
based upon tens of thousands of dollars for treating the
pneumonia after it has become established. Mortality remains
unchanged at N50% despite the use of the latest anti-fungaldrugs, and resistance to Aspergillus is already emerging. The
aerosol administration of an AmB based nanoparticle therefore
offers a targeted, cost-effective and patient friendly approach
which could be combined with a mini portable nebuliser for
home use. This compares very favourably with the daily
intravenous administration of AmB for several weeks in hospital
to treat established disease.
There is no vaccine for Aspergillus. Host protective immunity
depends upon a highly coordinated interaction between innate and
adaptive immunity. In normal mice exposed to A. fumigatus, a few
inflammatory infiltrates containing neutrophils and monocytes are
seen in the peribronchial region (Figure 3, B). This is because
Figure 6. Cytokines in immuno-suppressed BALB/c mouse lung after
pre-exposure prophylaxis with AP and day +2 after infection: (A) For
IFN-γ, no differences were seen. (B) TNF-α rose rapidly in immuno-sup-
pressed and infected mice over the course of the first 2 days after infection.
This time dependant increase was reduced by 90% in mice given AP
pre-exposure prophylaxis (P b 0.0001; n = 4). AF (d0) = 512 ± 41 copies/
105 copies HPRT; AF (d + 2) = 187,800 ± 61,500 copies/105 copies HPRT;
AF + AP (d0) = 531 ± 86 copies/105 copies HPRT; AF + AP (d + 1) =
2880 ± 596 copies/105 copies HPRT; AF + AP (d + 2) = 19,085 ± 2370
copies/105 copies HPRT. (C) iNOS did not increase in mice given AP
prophylaxis suggesting that lung alveolar macrophage activation did not
occur (n = 4). When compared to the iNOS in immuno-suppressed/infected
mice at day +2, iNOS was reduced by 90%.
Figure 7. Fungal burden in immuno-suppressed BALB/c mouse lung after
pre-exposure prophylaxis with AP at day +8 post infection. At day +8 after
infection, there was an increase in CFUs as compared to the CFUs on day +2
after infection (n = 4 mice/time point). However, this was 86% less that the
CFU count in mice on day +2 that had not received PA. For AF (d + 2), the
CFUs were 320,000 ± 64,400; for AF + AP (d + 2) the CFUs were 2800 ±
1880, and for AF + AP (d + 8) the CFUs were 45,200 ± 5760.
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incoming neutrophils; spores however can only be killed by resident
and activated alveolar macrophages.28 This contrasts with the
findings in hydrocortisone immuno-suppressed mice where numer-
ous septate branching hyphae penetrate into lung tissue to cause
bronchial wall damage and peribronchial necrosis (Figure 3, C).
Although some macromolecular polymers have immuno-
modulatory properties,29–31 we have reported that this is not the
case for 18.5 kDa PMA.6 We now show that this is also not the
case for any of the PMA polymers with MWts from 1.27 to
18.5 kDa. However, the pH dependant release of AmB from the
3.52 kDa AP nanoparticle was 40% greater at pH 5 than it was
from the 18.5 kDa AmB-PMA (Figure 1, C). This means that
more of the free and bioactive AmB was present in high
concentration in the macrophage endosome in which Aspergillus
survives and persists.
In immuno-competent mice, the 18.5 kDa AmB-PMA killed
leishmania amastigotes and the PMA in the macrophage
endosome enhanced the host’s T-helper type 1 (Th1) cytokine
response by stimulating IFN-γ production.6 This cytokine
enhanced parasite killing. In contrast, in this study of invasive
aspergillosis, hydrocortisone induced immuno-suppression led
to a marked suppression of Interferon Regulatory Factor (IRF)-1
(Supplementary Figure 3).32–34 This disabled the IFN-γ
mediated response in mouse lung to invasive aspergillosis.
Previous studies have shown the importance of IFN-γ in curing
aspergillosis: (i) In the steroid & cyclophosphamide based mouse
model of invasive aspergillosis, death was primarily associated
with high levels of TNF-α at the site of infection (i.e., lung)
coupled to a failure to generate a local and incremental IFN-γ
response35; (ii) In a steroid only based model of immuno-sup-
pression in BALB/c mice that were given IFN-γ replacement
therapy, it was the specific administration of exogenous IFN-γ
that decreased mortality.36 This has now been confirmed in
patients with invasive fungal infections.8,9,37Taken together,
Figure 8. Cytokines in immunosuppressed BALB/c mouse lung after
pre-exposure prophylaxis with AP at day +8 after infection: (A) For IFN-γ,
no differences were seen. (B) TNF-α at day +8 showed a small increase when
compared to day +2 after infection in mice with AP pre-exposure prophylaxis
(n = 4 mice/time point). AF (d + 2) = 187,800 ± 61,500 copies/105 copies
HPRT; AF + AP (d + 2) = 66,270 ± 2730 copies/105 copies HPRT;
AF + AP (d + 8) = 80,900 ± 7550 copies/105 copies HPRT.
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invasive aspergillosis.
In healthy mice, there is a primary phase of rapid and intense
clearance ofA. fumigatus by both resident alveolarmacrophages and
recruited neutrophils by the innate immune system. This phase is
associated with increased TNF-α.18 A second phase then follows
during which fungal debris is removed by incoming monocytes.
TNF-α returns to normal and healing of the lung occurs.However, in
steroid immuno-suppressed mice with invasive aspergillosis, it has
become clear that although TNF-α still plays an early and crucial
role, the clearance of spores by alveolar macrophages is altered by a
delay in the production of TNF-α.18 The outcome is invasion of lung
by hyphae, recruitment of numerous neutrophils, and widespread
tissue necrosis.38
Our animal model studies are based upon the use of aerosolised
AP as pre-exposure prophylaxis. In a study by Schmitt et al of
invasive aspergillosis in hydrocortisone immuno-suppressed rats
that were given aerosolised deoxycholate-AmB (Fungizone), asingle prophylactic dose of 1.6 mg/kg AmB was given 2 days
before infection.27 The result was 80% survival of mice at day +8.
Using their method ofAmBdose calculation, our daily inhaled dose
of AmB was 135 μg/kg making a total 3 day dose of 405 μg/kg;
this total dose of AmB was 75% less than the aerosolised dose of
deoxycholate-AmB (Fungizone) reported by Schmitt.27 Further-
more, using aerosolised AP rather than deoxycholate-AmB
(Fungizone) avoids the cytotoxic and lytic effects of deoxycholic
acid in the lung,6 as discussed below. AP also offers the additional
advantage of a slow, pHmediated, and tissue targeted release of the
active AmB in high concentration at the intracellular site where
fungal pathogens initiate infection, survive and persist. Taken
together, this means greater drug efficacy at the actual site of
infection at a lower dose administered.
Remarkably, we achieved 100% survival at day +8 with the
pre-exposure prophylaxis regimen described. However, the b1%
of persistingAspergillus spores in alveolar macrophages (Figure 3,
E and F) showed some evidence of spore germination (Figure 7).
Alveolar macrophages in normal healthy mice can rapidly clear
germinated aswell as ungerminatedA. fumigatus spores. However,
in steroid immuno-suppressed mice, some spores can start
germinating within 2-4 h of inhalation because they are not killed
by alveolar macrophages39,40; ungerminated spores have been
found in the lungs of those mice that survive infection. This is
consistent with our findings at day +2 (Figure 3, D-F) in mice
given pre-exposure prophylaxis with AP in that spores, but not
hyphae, were occasionally seen. It suggests that an effective
immune response is only generated against the hyphae of A.
fumigatus and that persisting non-germinating spores do not, of
themselves, initiate a host immune response in the lung.41 In this
specific context, it is important to note that AmB has no
anti-fungal activity against spores.42,43 This means that the
lungs cannot be completely sterilised of spores with AmB, or by
any other antifungal drug, and that some post-exposure
prophylaxis with AP is likely to be required to kill any
persisting spores if and when they start to germinate.
Several studies have reported on the use of aerosolised AmB as
both the deoxycholate and lipid formulations in rodents and
humans.44-47 Important factors for effective nebulisation of AmB
based drugs are particle size (diameter 2-5 μm) and use of an
isotonic solution in the nebuliser. Current clinical protocols
recommend that aerosolised AmB should be given three times a
day in a dose of 200 μg/kg every 8 h for the first month
post-transplant followed by a once daily dose of 500 μg/kg/day for
up to 6 months post-transplant.48 A worldwide survey of
antifungal prophylaxis in lung transplantation found that 58.6%
of centres were employing antifungal prophylaxis with 97.1%
specifically targeting Aspergillus species. Oral voriconazole alone
or in combination with inhaled AmB were the preferred first line
agents in current use. Six months post lung transplantation, 51.8%
of centres no longer used antifungal prophylaxis.49
The major side effects of the deoxycholate-AmB in current
clinical use are cough and bronchospasm.50 This is due to the
damage caused to the lung epithelial surface by the dose
dependent inhibition of surfactant function by deoxycholic
acid.51 Although liposomal AmB is better tolerated,52 there are
recent concerns about its use with particular reference to the lung
because it prevents IFITM3-mediated restriction of Influenza A
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interferons against Influenza A virus.53
In conclusion, PMA polymers and hydrogel capsules are in
increasingly widespread pharmaceutical use as a mature
biomaterial platform. Mixtures of oppositely charged polyelec-
trolytes can easily be made in water to form discrete and stable
nanoparticles with a polyanionic coat. This enables insoluble
and/or toxic drugs, like AmB, to be made into safe water soluble
nanoparticles. We have made an AP nanoparticle that is based
upon the use of very small 3.52 kDa PMA and AmB and have
shown that is not toxic to human or mouse cells of lung
epithelium and macrophage origin in both healthy mouse lung
and in Aspergillus infected lung. This study therefore provides
in-vivo proof of concept that very small and cost-effective
nanoparticles can be simply designed and developed for use as
pre-exposure prophylaxis agents to effectively deliver anti-mi-
crobial drugs to the lung.
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